Excalipoint Therapeutics has entered into a strategic partnership with DP Technology to co-develop a proprietary artificial intelligence (AI)-powered platform for the discovery of T-cell engagers (TCEs) and multi-specific antibodies.

The collaboration combines Excalipoint’s expertise in TCE engineering with DP Technology’s AI agent technology to improve the efficiency of TCE development and address key challenges in balancing treatment effectiveness and safety.

TCE development requires careful optimisation of several interconnected factors, including antigen-binding affinity, multi-specific valency and molecular structure. Conventional laboratory-based screening methods are often time-consuming and expensive.

The new platform will use Excalipoint’s proprietary TCE molecular libraries and preclinical datasets alongside DP Technology’s SciMaster and BioMaster AI systems. The integrated platform is designed to support molecular prediction, structural simulation, parameter optimisation and automated workflow management within Excalipoint’s proprietary molecular framework.

The AI platform will also enable dynamic adjustment of validation processes, helping to identify optimal molecular designs and improve the likelihood of successful clinical translation. In addition, it will automate tasks such as molecular ranking, format generation and reporting, while allowing researchers to focus on key scientific assessments, including cytokine release syndrome (CRS) risk and therapeutic window evaluation.

The platform will operate through a closed-loop Design–Build–Test–Learn (DBTL) process, where experimental data is continuously used to refine AI models and improve future molecular design.

Initially, the platform will support the advancement of Excalipoint’s TCE development pipeline. Over time, the company plans to expand its use across the entire drug discovery process, including target identification, pharmacology, toxicology assessment and clinical trial design.

The partnership forms part of Excalipoint’s broader strategy to integrate AI across its research and development activities, with the aim of accelerating the development of novel therapies for cancer and autoimmune diseases.

 

Source: businesswire.com

Report Abuse